Catalent Partners with Elpida Therapeutics to Advance AAV Gene Therapy for Ultra-Rare SPG50 Disease
Key Insights
Elpida Therapeutics (search) and Catalent announced a strategic partnership to support late-phase manufacturing of an AAV9 gene therapy (search) for Spastic Paraplegia Type 50 (search) (SPG50 (search)), an ultra-rare neurodegenerative disorder.
The collaboration ensures continued patient access to the SPG50 (search) therapy, with the final patient planned for treatment by the end of this year potentially marking the end of availability without this manufacturing support.
Catalent will utilize its UpTempo AAV manufacturing platform and receive exclusive manufacturing rights to Elpida's other pipeline AAV gene therapy programs.
Elpida Therapeutics (search), a non-profit biotechnology company developing gene therapies for ultra-rare diseases, has entered into a strategic partnership with Catalent, Inc. to support late-phase manufacturing of its lead AAV9 gene therapy (search) program for Spastic Paraplegia Type 50 (search) (SPG50 (search)). The collaboration addresses a critical manufacturing need that could have ended patient access to this therapy for an ultra-rare neurodegenerative disorder.
Critical Manufacturing Partnership Ensures Therapy Continuity
The partnership represents a pivotal moment for SPG50 (search) patients, as Terry Pirovolakis, Founder and Chief Executive Officer of Elpida Therapeutics (search), explained: "This collaboration with Catalent represents a critical step in ensuring continued patient access to our SPG50 gene therapy program. Without this support, the final patient planned for treatment by the end of this year could have marked the end of this therapy's availability."
Under the agreement, Catalent will not only support the SPG50 (search) program but also receive exclusive manufacturing rights to Elpida's other pipeline adeno-associated virus (AAV) gene therapy programs, expanding the scope of their collaboration beyond the lead indication.
Understanding SPG50: An Ultra-Rare Neurodegenerative Disorder
SPG50 (search) is an ultra-rare neurodegenerative disorder caused by AP4M1 (search) mutations that begins manifesting in infancy. The disease follows a devastating progression, with untreated patients developing cognitive impairment, epilepsy, and progressive paralysis by early adulthood. This severe clinical trajectory underscores the urgent need for effective therapeutic interventions.
Advanced Manufacturing Platform for Gene Therapy Production
Catalent will deploy its industry-leading UpTempo AAV manufacturing platform to support the SPG50 (search) program. This comprehensive platform incorporates several proprietary technologies, including a proprietary HEK293 cell line, pre-validated off-the-shelf AAV plasmids, and pre-qualified analytical assays designed to accelerate production timelines.
David McErlane, Biologics Group President for Catalent, emphasized the company's commitment to the partnership: "This partnership reflects Catalent's commitment to applying our broad gene therapy manufacturing expertise and Patient First approach to programs with significant unmet need. By leveraging our broad expertise in end-to-end AAV capabilities, we look forward to supporting Elpida's SPG50 (search) program through late-phase manufacturing so it can advance toward regulatory submission."
Regulatory Pathway and Manufacturing Expertise
The collaboration will focus on producing both R&D and GMP-grade material required for SPG50 (search) process validation, with Catalent also providing support for Elpida's Biologics License Application submission. This comprehensive approach addresses the complex manufacturing and regulatory requirements necessary for advancing gene therapies through late-phase development.
Catalent brings substantial experience to the partnership, having worked with clients on over 80 gene therapy programs. The company has successfully supported four commercial gene therapy programs to date, providing end-to-end services from early development through all clinical stages and commercialization.
Expanding Access to Ultra-Rare Disease Treatments
The partnership extends beyond immediate manufacturing needs, with Pirovolakis noting the broader implications: "Together, we are building a path to reach all patients living with SPG50 (search) and, ultimately, other devastating ultra-rare diseases." This vision aligns with the growing recognition of the need for sustainable manufacturing solutions for ultra-rare disease therapies, where traditional commercial models may not apply due to small patient populations.